

## VX21-522-001: A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

1. 18 to 65 years old 2. Stable cystic fibrosis disease 3. FEV1 at least 40% 4. Specific CFTR gene mutations

---

**Exclusion Criteria:**

1. Uncontrolled asthma in the last year 2. Oxygen saturation without oxygen therapy is >94% 3. Severe liver disease

### Conditions & Interventions

**Conditions:**

Rare Diseases, Breathing, Lung & Sleep Health

**Keywords:**

Cystic Fibrosis, CF

### More Information

**Description:** This is a clinical research study exploring the safety and tolerability of a single dose of VX-522 for people with cystic fibrosis (CF) who are not expected to benefit from CFTR modulators.

**Study Contact:** Mary Bailey - mpbailey@umn.edu

**Principal Investigator:** Joanne Billings

**IRB**

**Number:** SITE00001585

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.